Continued targeting of androgen receptor signalling: A rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Bianchini, Diletta ^a   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYPREGNENOLONE; 4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CORTICOTROPIN; CYTOCHROME P450; DEXAMETHASONE; DOCETAXEL; EPLERENONE; FLUTAMIDE; GONADORELIN DERIVATIVE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; NILUTAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TARGETING; FLUID RETENTION; GENE CONTROL; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; CARCINOMA; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RATIONALIZATION; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 80053229200     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70164-2     Document Type: Article

References (39)

1. A Jemal, S Siegel, E Ward, Y Hao, J Xu, T Murray Thun MX Cancer Statistics CA Cancer J Clin 58 2008 71 96 2008
2. C Huggins, C Stevens, CV Hodges Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Arch Surg 43 1941 209
3. IF Tannock, R de Wit, WR Berry et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer NEnglJMed 351 15 2004 Oct 7 1502 1512 (Pubitemid 39315317)
4. DP Petrylak, CM Tangen, MH Hussain et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer NEngl JMed 351 15 2004 Oct 7 1513 1520 (Pubitemid 39315318)
5. IF Tannock, D Osoba, MR Stockier et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 6 1996 Jun 1756 1764 (Pubitemid 26185452)
6. JA Locke, ES Guns, AA Lubik et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 68 2008 6407 6415
7. G Attard, AHM Reid, TA Yap et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
8. XT Isaacs, DS Coffey Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma Cancer Res 41 1981 5070 5075 (Pubitemid 12196676)
9. CD Chen, DS Welsbie, C Tran et al. Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39 (Pubitemid 38524696)
10. rd et al. The andró gen axis in recurrent prostate cancer Clin Cancer Res 10 2 2004 Jan 15 440 448 (Pubitemid 38173980)
11. G Attard, CS Cooper, JS de Bono Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16 6 2009 Dec 8 458 462
12. CJ Ryan, MR Smith, L Fong et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J Clin Oncol 28 2010 1481 1488
13. G Attard, AHM Reid, R A'Hern et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 2009 3742 3748
14. AHM Reid, G Attard, DC Danila et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol 28 2010 1489 1495
15. G Attard, J Richards, JS de Bono New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway Clin Cancer Res 17 7 2011 1649 1657
16. DC Danila, MJ Morris, JS de Bono et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
17. HI Scher, TM Beer, CS Higano Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
18. BJ Feldman, D Feldman The development of androgen-independent prostate cancer Nat Rev Cancer 1 1 2001 34 45 (Pubitemid 33741879)
19. SM Dehm, DJ Tindall Molecular regulation of androgen action in prostate cancer J Cell Biochem 99 2006 333 344 (Pubitemid 44435552)
20. AO Brinkmann, LJ Blok, PE de Ruiter et al. Mechanisms of androgen receptor activation and function J Steroid Biochem MolBiol 69 1999 307 313 (Pubitemid 29305551)
21. A Hobisch, Z Culig, C Radmayr et al. Distant métastases from prostatic carcinoma express androgen receptor protein Cancer Res 55 1995 3068 3072
22. JA Locke, ES Guns, AA Lubik et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 68 15 2008 6407 6415
23. T Hara, J Miyazaki, H Araki et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome Cancer Res 63 l 2003 149 153 (Pubitemid 36070433)
24. SM Dehm, LJ Schmidt, HV Heemers et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance Cancer Res 68 13 2008 5469 5477
25. Z Guo, X Yang, F Sun et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Cancer Res 69 2009 2305 2313
26. R Hu, TA Dunn, S Wei et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormonerefractory prostate cancer Cancer Res 69 2009 16 22
27. AS Perry, RW Watson, M Lawler et al. The epigenome as a therapeutic target in prostate cancer Nat Rev Urol 7 12 2010 668 680
28. RB Montgomery, EA Mostaghel, R Vessella et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447 4454
29. WD Figg, Y Liu, P Arlen et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone métastases J Urol 173 3 2005 790 796 (Pubitemid 40239343)
30. GA Potter, SE Barrie, M Jarman et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer J Med Chem 38 1995 2463 2471
31. RJ Auchus The genetics, pathophysiology, and management of human deficiencies of P450cl7 Endocrinol Metab Clin North Am 30 2001 101 119 (Pubitemid 32381716)
32. G Attard, AHM Reid, JS de Bono Abiraterone acetate is well tolerated without concomitant use of corticosteroids J Clin Oncol 28 2010 560 561
33. M Yamaoka, T Hara, M Kusaka Overcoming persistent dependency on androgen signalling after progression to castration resistant prostate cancer Clin Cancer Res 16 2010 4319 4324
34. JS de Bono, CJ Logothetis, K Fizazi et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (Pts) with metastatic castration resistant prostate cancer (MCRPC) who have progressed after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study Ann Oncol 21 Suppl 8 2010 LBA5
35. R Dreicer, DB Agus, GR MacVicar et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study J Clin Oncol 28 15 suppl 2010 254s (abstract 3084).
36. VD Handratta, TS Vasaitis, VCO Njar et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model JMed Chem 48 2005 2972 2984 (Pubitemid 40552912)
37. CS Howard, PB Steven Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer Cancer Cell 15 6 2009 461 463
38. MC Hodgson, HC Shen, AN Hollenberg et al. Structural basis for nuclear receptor co-repressor recruitment by antagonist-liganded androgen receptor Mol Cancer Ther 7 2008 3187 3194
39. Y Chen, NJ Clegg, HI Sher Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol 10 10 2009 981 991